According to a media release issued yesterday by the National Institutes of Health, the CHAARTED clinical trial has shown that men with hormone-sensitive, metastatic prostate cancer who received docetaxel chemotherapy at the start of standard androgen deprivation therapy (ADT) lived longer than patients who received ADT alone. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, chemotherapy, docetaxel, metastaic | 17 Comments »